Nyxoah Sa ( (NYXH) ) has released its Q4 earnings. Here is a breakdown of the information Nyxoah Sa presented to its investors.
Nyxoah SA is a medical technology company specializing in innovative neuromodulation treatments for Obstructive Sleep Apnea (OSA), with its flagship product being the Genio® system, a battery-free hypoglossal neuromodulation device.
In its latest earnings report, Nyxoah announced financial results for the fourth quarter and full year 2024, highlighting significant progress towards its U.S. commercial launch and a nearing conclusion of its FDA PMA application review.
The company reported fourth-quarter revenue of €1.3 million and full-year revenue of €4.5 million, excluding deferred revenue. The gross margin for the fourth quarter stood at 73%, and the company’s cash and financial assets increased to €85.6 million by the end of 2024. Nyxoah also expanded its U.S. executive leadership team and commercial organization in preparation for its market entry.
Despite an operating loss of €58.8 million for the year, driven by increased R&D and commercialization expenses, Nyxoah remains optimistic about its future. The company is poised for a U.S. market launch of its Genio® system, aiming to address the needs of millions of Americans with moderate to severe OSA.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com